Literature DB >> 10767244

Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype.

S R Thomas1, S A Kharitonov, S F Scott, M E Hodson, P J Barnes.   

Abstract

STUDY
OBJECTIVES: Inducible nitric oxide synthase (iNOS) is upregulated in a number of inflammatory lung conditions, and exhaled nitric oxide (NO) concentration is increased. However, previous studies in children with cystic fibrosis (CF) have shown that exhaled NO is reduced. The purpose of this investigation was to study exhaled NO concentration in adults with CF, and to investigate the effect of CF genotype and respiratory tract infection on this measurement.
DESIGN: Exhaled and nasal NO levels were measured in 54 adult CF subjects and 37 healthy nonsmoking age-matched subjects using a chemiluminesence analyzer. Spirometry (FEV(1) and FVC), CF genotype, and bacterial colonization were also recorded.
SETTING: This study was conducted at a national CF center.
RESULTS: The mean age of patients was 26.9 years, and the mean FEV(1) was 50.5% predicted (range, 17 to 104%). Nasal NO in the CF patients (mean, 520 parts per billion [ppb]; confidence interval [CI], 452 to 588) was significantly lower (p < 0.001) than in control subjects (987 ppb; CI, 959 to 1,015). Exhaled NO was significantly lower (p < 0. 001) in CF patients (5.0 ppb; CI, 4.1 to 6.1) than in control subjects (7.3 ppb; CI, 6.8 to 7.8). FEV(1) did not correlate with nasal or exhaled NO. No association was observed between genotype and NO values or colonization with Pseudomonas aeruginosa.
CONCLUSIONS: Despite the airway inflammation that is characteristic of CF, both nasal and exhaled NO were reduced. There was no association with genotype or infection status. As NO has bacteriostatic effects and may augment mucociliary clearance, this observation may be of clinical importance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767244     DOI: 10.1378/chest.117.4.1085

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

Review 1.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

2.  Nasal NO measurement by direct sampling from the nose during breathhold: Aspiration flow, nasal resistance and reproducibility.

Authors:  V M D Struben; M H Wieringa; C J Mantingh; J C de Jongste; L Feenstra
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-19       Impact factor: 2.503

Review 3.  Phenotypes of Chronic Rhinosinusitis.

Authors:  Seong H Cho; Daniel L Hamilos; Doo Hee Han; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol Pract       Date:  2020-05

4.  Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis.

Authors:  Katharine E A Darling; Thomas J Evans
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

5.  Extended nitric oxide measurements in exhaled air of cystic fibrosis and healthy adults.

Authors:  Markus Hofer; Luzia Mueller; Thomas Rechsteiner; Christian Benden; Annette Boehler
Journal:  Lung       Date:  2009-08-08       Impact factor: 2.584

6.  Nasal Nitric Oxide in Primary Immunodeficiency and Primary Ciliary Dyskinesia: Helping to Distinguish Between Clinically Similar Diseases.

Authors:  Zofia N Zysman-Colman; Kimberley R Kaspy; Reza Alizadehfar; Keith R NyKamp; Maimoona A Zariwala; Michael R Knowles; Donald C Vinh; Adam J Shapiro
Journal:  J Clin Immunol       Date:  2019-03-26       Impact factor: 8.317

7.  Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis.

Authors:  J Texereau; S Marullo; D Hubert; J Coste; D J Dusser; J Dall'Ava-Santucci; A T Dinh-Xuan
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

8.  Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia.

Authors:  I Horváth; S Loukides; T Wodehouse; E Csiszér; P J Cole; S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

9.  Assessment of airway inflammation with exhaled NO measurement.

Authors:  E Hatziagorou; J Tsanakas
Journal:  Hippokratia       Date:  2007-04       Impact factor: 0.471

Review 10.  The role of inhaled corticosteroids in the management of cystic fibrosis.

Authors:  Kristie R Ross; James F Chmiel; Michael W Konstan
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.